Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

A-1331852

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

Bcl-xL inhibitor

Related drugs:

TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	A-1331852 Sensitive: C3 – Early Trials A-1331852 Sensitive : C3	A-1331852 Sensitive: C3 – Early Trials A-1331852 Sensitive : C3
BCL2 overexpression	Multiple Myeloma	BCL2 overexpression	Multiple Myeloma	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D
MCL1 underexpression	Multiple Myeloma	MCL1 underexpression	Multiple Myeloma	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D
BCL2L1 underexpression	Multiple Myeloma	BCL2L1 underexpression	Multiple Myeloma	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	S63845 + A-1331852 Sensitive: D – Preclinical S63845 + A-1331852 Sensitive : D	S63845 + A-1331852 Sensitive: D – Preclinical S63845 + A-1331852 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	RG7440 + A-1331852 Sensitive: D – Preclinical RG7440 + A-1331852 Sensitive : D	RG7440 + A-1331852 Sensitive: D – Preclinical RG7440 + A-1331852 Sensitive : D